RxDoctor Payments Data

Kenneth Paige, DO

Family Medicine · Sun Lakes, AZNPI 1487645685

Payments from drug & device makers

$6,870in general payments, 2019–2025

Across 425 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$668
  • Amgen$456
  • AstraZeneca$412
  • Novartis$343
  • Novo Nordisk$329
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,76698%
  • Education$1042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,870 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$386,203
Medicare patients
1,246
Services billed
5,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$143,864
EliquisApixaban79$87,866
FarxigaDapagliflozin Propanediol70$79,830
TrulicityDulaglutide33$61,342
XareltoRivaroxaban41$50,212
JanuviaSitagliptin Phosphate44$47,043
ProliaDenosumab26$45,274
RybelsusSemaglutide25$45,011
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$44,859
JardianceEmpagliflozin21$36,287
MyrbetriqMirabegron32$27,377
Tresiba Flextouch U-200Insulin Degludec16$19,963
JanumetSitagliptin Phos/Metformin Hcl19$18,873
GemtesaVibegron15$18,125
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$16,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$329$188,875112 claims
PfizerEliquis$271$87,86679 claims
AstraZenecaFarxiga$412$79,83070 claims
MerckJanuvia, Janumet$144$65,91663 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$668$65,46276 claims
Lilly USA, LLCTrulicity, Humalog$208$63,73550 claims
Johnson & JohnsonXarelto$47$50,21241 claims
AmgenProlia$456$45,27426 claims
Boehringer IngelheimJardiance$307$36,28721 claims
Astellas Pharma US IncMyrbetriq$244$27,37732 claims
Sumitomo Pharma America, Inc.Gemtesa$64$18,12515 claims
AbbVieSynthroid$1,418$3,09362 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Sun Lakes

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →